Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (vasoflux international trial for acute myocardial infarction lysis)

American Heart Journal

Volumn 142, Issue 2, 2001, Pages 237-243

  Peters, Ron J G ^a   Spickler, William ^b   Théroux, Pierre ^c   White, Harvey ^d   Gibson, Michael ^e   Molhoek, Peter G ^f   Anderson, H Vernon ^g   Weitz, Jeffrey I ^h   Hirsh, Jack ^h   Weaver, W Douglas ⁱ  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Vascular Therapeutics Inc   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

^d GREEN LANE HOSPITAL   (New Zealand)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g UNIVERSITY OF TEXAS   (United States)

^h HAMILTON HEALTH SCIENCES   (Canada)

ⁱ HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 9A; HEPARIN; HEPARIN COFACTOR II; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; UNCLASSIFIED DRUG; VASOFLUX;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; NEW ZEALAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UNITED STATES;

EID: 0034900605     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.116759     Document Type: Article

References (28)

1. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration
2. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
3. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
4. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
5. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 1 OB Investigators
6. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial
7. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
8. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis
9. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase
10. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
11. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
12. Vasoflux, a new anticoagulant with a novel mechanism of action
13. Vasoflux, a novel anticoagulant that is more effective than heparin and safer than hirudin in rabbits
14. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
15. TIMI frame count: A quantitative method of assessing coronary artery flow
16. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
17. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
18. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction
19. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
20. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
21. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
22. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
23. Clinical trials of low molecular weight heparins
24. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: The FATIMA study
25. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardical infarction - A pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II)
26. Heparins and Aspirin Reperfusion Therapy in patients With acute Myocardial Infarction Study (HART) 2 study
27. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
28. Combined therapy with streptokinase and integrilin